Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (111-120 of 312) with videos related to

Pageof 32
Sort By:
Therapeutic Advances in Medical Oncology|May 25, 2026
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancerMehmet A Bilen, Benjamin H Lowentritt, Sabree Burbage, et al.
BJU International|March 19, 2016
Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancerNeal D Shore, Franklin Chu, Judd Moul, et al.
Future Oncology (London, England)|April 29, 2026
Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancerNeal D Shore, Nasreen Khan, Rana R McKay, et al.
Advances in Therapy|November 28, 2025
Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Cancer Control : Journal of the Moffitt Cancer Center|January 11, 2013
Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancerNeal D Shore, Constantine A Mantz, Daniel E Dosoretz, et al.
Advances in Therapy|May 29, 2025
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate CancerMehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Journal of Comparative Effectiveness Research|May 9, 2025
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USABenjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, et al.
Clinical Genitourinary Cancer|November 8, 2017
Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver SurveyLawrence Drudge-Coates, William K Oh, Bertrand Tombal, et al.
Urologic Oncology|June 25, 2021
Non-muscle-invasive bladder cancer: An overview of potential new treatment optionsNeal D Shore, Joan Palou Redorta, Gregoire Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2023
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trialKarim Fizazi, Neal D Shore, Matthew Smith, et al.
Pageof 32

Showing results (111-120 of 312) with videos related to

Sort By:
Pageof 32
Therapeutic Advances in Medical Oncology|May 25, 2026
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancerMehmet A Bilen, Benjamin H Lowentritt, Sabree Burbage, et al.
BJU International|March 19, 2016
Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancerNeal D Shore, Franklin Chu, Judd Moul, et al.
Future Oncology (London, England)|April 29, 2026
Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancerNeal D Shore, Nasreen Khan, Rana R McKay, et al.
Advances in Therapy|November 28, 2025
Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Cancer Control : Journal of the Moffitt Cancer Center|January 11, 2013
Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancerNeal D Shore, Constantine A Mantz, Daniel E Dosoretz, et al.
Advances in Therapy|May 29, 2025
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate CancerMehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Journal of Comparative Effectiveness Research|May 9, 2025
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USABenjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, et al.
Clinical Genitourinary Cancer|November 8, 2017
Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver SurveyLawrence Drudge-Coates, William K Oh, Bertrand Tombal, et al.
Urologic Oncology|June 25, 2021
Non-muscle-invasive bladder cancer: An overview of potential new treatment optionsNeal D Shore, Joan Palou Redorta, Gregoire Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2023
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trialKarim Fizazi, Neal D Shore, Matthew Smith, et al.
Pageof 32